Aksigorta A.S. (IST:AKGRT)
Turkey · Delayed Price · Currency is TRY 6.52
-0.33 (-4.82%)
Aug 14, 2025, 4:43 PM GMT+3
Marinus Pharmaceuticals Income Statement
Financials in millions TRY. Fiscal year is January - December.
Millions TRY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Premiums & Annuity Revenue | 10,060 | 10,277 | 7,677 | 4,912 | 3,294 | 2,737 | Upgrade |
Total Interest & Dividend Income | 476.3 | 1,166 | 881.37 | 418.57 | 372.07 | 200.26 | Upgrade |
Gain (Loss) on Sale of Investments | 2,786 | 2,786 | 1,089 | 607.86 | 128.25 | 82.27 | Upgrade |
Other Revenue | 387.49 | 387.49 | 129.24 | 153.5 | 192.19 | 137.53 | Upgrade |
| 13,710 | 14,617 | 9,776 | 6,092 | 3,986 | 3,157 | Upgrade | |
Revenue Growth (YoY) | 13.91% | 49.51% | 60.48% | 52.82% | 26.27% | 18.00% | Upgrade |
Policy Benefits | 9,284 | 8,983 | 6,553 | 5,299 | 3,071 | 1,766 | Upgrade |
Depreciation & Amortization | 165.26 | 165.26 | 93.72 | 61.1 | 43.92 | 52.63 | Upgrade |
Selling, General & Administrative | 2,512 | 2,846 | 1,933 | 1,063 | 670.63 | 597.73 | Upgrade |
Other Operating Expenses | 1,199 | 1,199 | 868.92 | 440.7 | 202.72 | 203.26 | Upgrade |
Total Operating Expenses | 13,161 | 13,194 | 9,448 | 6,864 | 3,989 | 2,620 | Upgrade |
Operating Income | 549.38 | 1,423 | 328.08 | -771.98 | -2.4 | 536.99 | Upgrade |
Currency Exchange Gain (Loss) | 417.65 | 417.65 | 908.72 | 442.6 | 249.47 | 30.5 | Upgrade |
Other Non Operating Income (Expenses) | 173.13 | 31.13 | 21.89 | 16.75 | 4.74 | 3.27 | Upgrade |
EBT Excluding Unusual Items | 1,140 | 1,872 | 1,259 | -312.62 | 251.81 | 570.75 | Upgrade |
Pretax Income | 1,140 | 1,872 | 1,259 | -312.62 | 251.81 | 570.75 | Upgrade |
Income Tax Expense | -114.42 | 15.58 | 73.52 | -185.28 | 62.41 | 126.79 | Upgrade |
Net Income | 1,255 | 1,857 | 1,185 | -127.35 | 189.4 | 443.97 | Upgrade |
Net Income to Common | 1,255 | 1,857 | 1,185 | -127.35 | 189.4 | 443.97 | Upgrade |
Net Income Growth | 0.46% | 56.65% | - | - | -57.34% | 21.18% | Upgrade |
Shares Outstanding (Basic) | 1,612 | 1,612 | 1,612 | 1,612 | 612 | 612 | Upgrade |
Shares Outstanding (Diluted) | 1,612 | 1,612 | 1,612 | 1,612 | 612 | 612 | Upgrade |
Shares Change (YoY) | - | - | - | 163.40% | - | - | Upgrade |
EPS (Basic) | 0.78 | 1.15 | 0.74 | -0.08 | 0.31 | 0.73 | Upgrade |
EPS (Diluted) | 0.78 | 1.15 | 0.74 | -0.08 | 0.31 | 0.73 | Upgrade |
EPS Growth | 0.46% | 56.65% | - | - | -57.34% | 21.18% | Upgrade |
Free Cash Flow | - | 3,983 | 2,032 | 1,234 | 484.55 | 403.69 | Upgrade |
Free Cash Flow Per Share | - | 2.47 | 1.26 | 0.77 | 0.79 | 0.66 | Upgrade |
Operating Margin | 4.01% | 9.74% | 3.36% | -12.67% | -0.06% | 17.01% | Upgrade |
Profit Margin | 9.15% | 12.70% | 12.12% | -2.09% | 4.75% | 14.06% | Upgrade |
Free Cash Flow Margin | - | 27.25% | 20.78% | 20.25% | 12.16% | 12.79% | Upgrade |
EBITDA | 793.67 | 1,555 | 409.38 | -723.03 | 33.13 | 580.22 | Upgrade |
EBITDA Margin | 5.79% | 10.64% | 4.19% | -11.87% | 0.83% | 18.38% | Upgrade |
D&A For EBITDA | 244.29 | 131.43 | 81.3 | 48.95 | 35.53 | 43.23 | Upgrade |
EBIT | 549.38 | 1,423 | 328.08 | -771.98 | -2.4 | 536.99 | Upgrade |
EBIT Margin | 4.01% | 9.74% | 3.36% | -12.67% | -0.06% | 17.01% | Upgrade |
Effective Tax Rate | - | 0.83% | 5.84% | - | 24.78% | 22.21% | Upgrade |
Source: S&P Global Market Intelligence. Insurance template. Financial Sources.